We rely on CDMOs over whom we have limited control. Should the cost, delivery and quality of clinical materials manufactured by us in our Fall River facility or supplied by CDMOs vary to our disadvan…
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representa…
Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri…
Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab…
Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS g…
The Company recognized $ 0.0 million and $ 0.6 million in revenue under the agreements with Rockefeller during the three months ended March 31, 2026, and 2025, respectively.
Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab…
Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa…
gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drugs or import bans. The regulatory requirements and policies may change and additiona…
Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drug…
ce obligations in the contract; and ● Recognition of revenue when, or as, the Company satisfies a performance obligation. Revenue for the Company is derived from product development agreements with c…
Celldex Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CLDX-DEBT
Debt stack $1.9M
90%
Market cache reports total debt of $1.9M.
Celldex Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Celldex Therapeutics, Inc..
Celldex Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CLDX-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP
WELLINGTON MANAGEMENT GROUP LLP
90%
13F overlay lists WELLINGTON MANAGEMENT GROUP LLP as top holder; 232 tracked holders.
Celldex Therapeutics, Inc. Extended Supply Chain Network
